No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
QNCX Quince Therapeutics
- 0.680
- -0.030-4.23%
Close Jun 18 16:00 ET
- 0.700
- +0.020+2.94%
Post 19:10 ET
29.39MMarket Cap-894P/E (TTM)
0.710High0.680Low139.21KVolume0.700Open0.710Pre Close96.55KTurnover0.47%Turnover RatioLossP/E (Static)43.22MShares1.70052wk High0.40P/B20.06MFloat Cap0.65152wk Low--Dividend TTM29.49MShs Float121.980Historical High--Div YieldTTM4.23%Amplitude0.540Historical Low0.693Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
FDA Fast Tracks Quince Therapeutics' Rare Ataxia Drug EryDex
Express News | FDA Grants Fast Track Designation To Quince Therapeutics' EryDex System To Treat Ataxia-Telangiectasia
Express News | Quince Therapeutics Receives U.S. FDA Fast Track Designation for Erydex System
Quince Therapeutics | 10-Q: Quarterly report
Express News | Quince Therapeutics - Expects Its Existing Cash Runway to Be Sufficient to Fund Company's Capital Efficient Development Plan Into 2026
Quince Therapeutics 1Q Loss/Shr 26c >QNCX
Quince Therapeutics 1Q Loss/Shr 26c >QNCX
Comments
$Quince Therapeutics(QNCX.US$ Benzinga· 1 min FDA Grants Fast Track Designation To Quince Therapeutics' EryDex System To Treat Ataxia-Telangiectasia
$Quince Therapeutics(QNCX.US$
I would wait to see what it does after the bell. Either way keep this on your watchlist. It will run at some point. Aquisition agreement and the chart is ripe for a run.
I would wait to see what it does after the bell. Either way keep this on your watchlist. It will run at some point. Aquisition agreement and the chart is ripe for a run.
7
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg